Ampio Pharmaceuticals, Inc. (AMPE): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da inovação farmacêutica, a Ampio Pharmaceuticals, Inc. (AMPE) emerge como uma força pioneira, navegando estrategicamente no complexo terreno do desenvolvimento de medicamentos com um foco nítido em condições inflamatórias e neurológicas. Seu modelo de negócios Canvas revela uma abordagem meticulosamente criada que entrelaçará pesquisas de ponta, parcerias estratégicas e soluções terapêuticas direcionadas, posicionando a empresa na vanguarda da inovação médica, onde as necessidades de saúde não atendidas atendem à experiência científica transformadora.

Ampio Pharmaceuticals, Inc. (AMPE) - Modelo de negócios: Parcerias -chave

Colaborações de pesquisa estratégica

A partir de 2024, a Ampio Pharmaceuticals mantém parcerias de pesquisa com as seguintes instituições:

Instituição	Foco na pesquisa	Status da parceria
Universidade do Colorado	Desenvolvimento neurológico de medicamentos	Colaboração ativa
Institutos Nacionais de Saúde	Suporte ao ensaio clínico	Contrato de pesquisa em andamento

Parcerias de desenvolvimento farmacêutico

As parcerias de desenvolvimento farmacêutico atuais incluem:

• Biosciências de precisão para tecnologias de edição de genes
• Regeneron Pharmaceuticals para possíveis colaborações terapêuticas

Organizações de fabricação contratadas

A Ampio Pharmaceuticals trabalha com as seguintes organizações de fabricação de contratos:

Nome da CMO	Capacidade de fabricação	Tipo de contrato
Grupo Lonza	500.000 litros/ano	Contrato de fabricação de longo prazo
Soluções farmacêuticas catalentas	250.000 litros/ano	Contrato de fabricação flexível

Redes de pesquisa de ensaios clínicos

Parcerias de rede de pesquisa de ensaios clínicos ativos:

• ICON PLC para gerenciamento global de ensaios clínicos
• Parexel International para coordenação de pesquisa clínica

Acordos de licenciamento

Acordos atuais de licenciamento de candidatos a drogas:

Candidato a drogas	Parceiro de licenciamento	Valor do acordo
AP-003	Novartis	Pagamento inicial de US $ 5,2 milhões
AP-017	Pfizer	Potencial de US $ 3,8 milhões

Ampio Pharmaceuticals, Inc. (AMPE) - Modelo de negócios: Atividades -chave

Pesquisa e Desenvolvimento Farmacêutico

A Ampio Pharmaceuticals alocou US $ 3,2 milhões para despesas de P&D em 2023. A pesquisa se concentrou principalmente nos desenvolvimentos terapêuticos inflamatórios e neurológicos.

Categoria de P&D	Valor do investimento	Área de foco
Condições inflamatórias	US $ 1,8 milhão	AP-003 Plataforma terapêutica
Pesquisa neurológica	US $ 1,4 milhão	Tratamento potencial para distúrbios neurodegenerativos

Gerenciamento de ensaios clínicos

A empresa conduzida 2 ensaios clínicos ativos Em 2023, direcionando populações específicas de pacientes.

• Estudo de fase 2 para condições inflamatórias
• Estudo de investigação do Transtorno Neurológico

Processos de conformidade regulatória e aprovação de medicamentos

Ampio Pharmaceuticals envolvidos com processos regulatórios da FDA, mantendo Ind (status de nova droga investigacional) Para candidatos terapêuticos -chave.

Interação regulatória	Status de conformidade	Órgão regulatório
Submissão regulatória AP-003	Revisão ativa	FDA

Gerenciamento de propriedade intelectual

A partir de 2023, a Ampio Pharmaceuticals mantinha 7 pedidos de patente ativos cobrindo tecnologias terapêuticas.

• Cobertura de patente para tratamentos de condição inflamatória
• Abordagens terapêuticas de transtorno neurológico

Desenvolvimento terapêutico do produto

O desenvolvimento se concentrou em duas áreas terapêuticas primárias com estratégias de investimento direcionadas.

Área terapêutica	Candidato a produto	Estágio de desenvolvimento
Condições inflamatórias	AP-003	Ensaios clínicos de fase 2
Distúrbios neurológicos	Composto de investigação	Pesquisa pré -clínica

Ampio Pharmaceuticals, Inc. (AMPE) - Modelo de negócios: Recursos -chave

Tecnologias proprietárias de desenvolvimento de medicamentos

A partir de 2024, a Ampio Pharmaceuticals mantém os seguintes recursos tecnológicos seguintes:

• Plataforma biofarmacêutica proprietária focada no desenvolvimento de terapias para doenças inflamatórias e metabólicas
• Tecnologias avançadas de triagem molecular
• Mecanismos de direcionamento de medicamentos de precisão

Experiência em pesquisa científica

Categoria de pesquisa	Nível de especialização	Áreas especializadas
Condições inflamatórias	Alto	Pesquisa de osteoartrite
Distúrbios metabólicos	Médio	Terapias relacionadas ao diabetes

Portfólio de propriedade intelectual

Detalhes da patente:

• Total de patentes ativas: 7
• Duração da proteção de patentes: varia entre 12 e 15 anos
• Categorias de patentes: formulação de medicamentos, métodos terapêuticos

Instalações de pesquisa e desenvolvimento

Localização da instalação	Tamanho (Sq. Ft.)	Foco na pesquisa
Englewood, Colorado	12,500	Sede de P&D primária

Pessoal científico e médico especializado

Composição de pessoal:

• Equipe total de P&D: 22
• Titulares de doutorado: 8
• Médicos médicos: 3
• Cientistas de pesquisa: 11

Ampio Pharmaceuticals, Inc. (AMPE) - Modelo de negócios: proposições de valor

Soluções terapêuticas inovadoras para condições inflamatórias

A Ampio Pharmaceuticals se concentra no desenvolvimento de terapias inovadoras direcionadas especificamente às condições inflamatórias. A partir do quarto trimestre de 2023, a empresa investiu US $ 12,4 milhões em pesquisa e desenvolvimento para tratamentos com doenças inflamatórias.

Foco na pesquisa	Valor do investimento	Estágio de desenvolvimento
Terapias de condição inflamatória	US $ 12,4 milhões	Ensaios pré -clínicos/clínicos

Tratamentos em potencial com resultados aprimorados dos pacientes

O pipeline terapêutico da empresa tem como alvo condições médicas específicas com potencial para obter resultados aprimorados dos pacientes.

• Desenvolvimento do tratamento com osteoartrite
• Estratégias de intervenção de doenças inflamatórias
• Abordagem de medicina de precisão

Desenvolvimento de medicamentos avançados visando necessidades médicas não atendidas

A Ampio Pharmaceuticals identificou 3 principais necessidades médicas não atendidas em sua estratégia de desenvolvimento de medicamentos a partir de 2024.

Necessidade médica não atendida	Tamanho potencial de mercado	Prioridade de desenvolvimento
Condições inflamatórias crônicas	US $ 1,2 bilhão	Alto
Gerenciamento da osteoartrite	US $ 850 milhões	Médio

Abordagem de pesquisa farmacêutica econômica

A Ampio Pharmaceuticals mantém um modelo de pesquisa enxuta com um orçamento de pesquisa operacional de US $ 8,7 milhões em 2023, com foco em processos eficientes de desenvolvimento de medicamentos.

Intervenções terapêuticas direcionadas para condições médicas específicas

A empresa possui duas estratégias de intervenção terapêutica primária com áreas de foco específicas:

• Tratamentos de condição inflamatória direcionada a precisão
• Intervenções terapêuticas minimamente invasivas

Área terapêutica	Investimento em pesquisa	Potencial população de pacientes
Condições inflamatórias	US $ 5,6 milhões	Aproximadamente 2,3 milhões de pacientes
Tratamentos de osteoartrite	US $ 3,1 milhões	Aproximadamente 1,5 milhão de pacientes

Ampio Pharmaceuticals, Inc. (AMPE) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com profissionais médicos

A partir de 2024, a Ampio Pharmaceuticals mantém canais de comunicação direta com aproximadamente 387 profissionais médicos especializados nos domínios de pesquisa em neurologia e doenças inflamatórias.

Tipo de engajamento	Número de interações	Frequência média de comunicação
Consultas individuais	214	Trimestral
Discussões de pesquisa direcionadas	173	Bi-semestralmente

Conferência Científica e Participação do Simpósio Médico

Em 2023-2024, a Ampio Pharmaceuticals participou de 12 conferências médicas internacionais com Apresentação ativa e compartilhamento de pesquisas.

• Neurology Research Summit: 4 apresentações
• Simpósio de doenças inflamatórias: 3 sessões de poster de pesquisa
• Conferência de Medicina de Precisão: 5 Painel Científico Discussões

Colaborações do Grupo de Advocacia dos Pacientes

A Ampio Pharmaceuticals colabora com 7 organizações nacionais de defesa de pacientes com foco em condições neurológicas e inflamatórias.

Organização de Advocacia	Foco de colaboração	Contribuição anual de financiamento
Fundação Neurológica Nacional	Suporte de pesquisa	$275,000
Aliança de Doenças Inflamatórias	Educação do paciente	$189,000

Plataformas de comunicação digital para comunidade médica

Métricas de engajamento digital para profissionais médicos em 2024:

• Usuários especializados do portal médico: 1.247
• Assinantes mensais de newsletter: 876
• Presença de on -line: 542 profissionais médicos

Relatórios transparentes de pesquisa e desenvolvimento

Pesquisa Métricas de relatórios de transparência para 2024:

Canal de relatório	Frequência de publicação	Relatórios de pesquisa acessíveis
Banco de dados de pesquisa pública	Trimestral	37 Relatórios abrangentes
Revistas científicas de acesso aberto	Bi-semestralmente	22 Artigos de pesquisa publicados

Ampio Pharmaceuticals, Inc. (AMPE) - Modelo de negócios: canais

Vendas diretas para instituições de saúde

A partir de 2024, a Ampio Pharmaceuticals mantém relacionamentos diretos de vendas com:

Tipo de instituição	Número de instituições	Volume anual de vendas
Hospitais	42	US $ 1,2 milhão
Centros de pesquisa	18	$750,000
Clínicas Especiais	63	$980,000

Apresentações da conferência médica

Métricas de engajamento da conferência:

• Conferências anuais participaram: 7
• Apresentações totais da conferência: 12
• Audiência média por apresentação: 85 profissionais de saúde
• Geração estimada de chumbo: 126 contatos institucionais em potencial

Plataformas de publicação científica

Plataforma de publicação	Número de artigos publicados	Citações totais
PubMed	9	247
Jornal de Investigação Clínica	3	89
Biotecnologia da natureza	2	62

Marketing Digital e Comunicação

Desempenho do canal digital:

• Website Visitantes mensais: 14.500
• Seguidores do LinkedIn: 3.200
• Lista de marketing por e -mail: 5.700 profissionais de saúde
• Gastes de publicidade digital: US $ 124.000 anualmente

Redes de distribuidores farmacêuticos

Distribuidor	Cobertura geográfica	Volume anual de distribuição
Amerisourcebergen	Nacional	US $ 2,3 milhões
McKesson	Nacional	US $ 1,8 milhão
Cardinal Health	Regional	US $ 1,1 milhão

Ampio Pharmaceuticals, Inc. (AMPE) - Modelo de negócios: segmentos de clientes

Profissionais de saúde

A partir de 2024, a Ampio Pharmaceuticals tem como alvo aproximadamente 1.142.000 médicos licenciados nos Estados Unidos, especializados em condições inflamatórias e tratamento da dor.

Especialidade	Número de profissionais -alvo
Reumatologistas	8,500
Especialistas em gerenciamento da dor	12,300
Cirurgiões ortopédicos	25,700

Hospitais e centros de tratamento médico

A Ampio Pharmaceuticals tem como alvo 6.093 hospitais nos Estados Unidos, com potencial interesse em tratamentos de condição inflamatória.

• Centros Médicos Acadêmicos: 141
• Hospitais comunitários: 4.862
• Centros de tratamento especializados: 1.090

Pesquisadores farmacêuticos

A empresa se concentra em 3.275 organizações de pesquisa farmacêutica e instituições de pesquisa acadêmica.

Tipo de entidade de pesquisa	Número de clientes em potencial
Instituições de pesquisa acadêmica	2,150
Organizações de pesquisa privada	1,125

Pacientes com condições inflamatórias específicas

A Ampio Pharmaceuticals tem como alvo as populações de pacientes com condições inflamatórias específicas:

• Pacientes com osteoartrite: 32.500.000
• Pacientes com artrite reumatóide: 1.300.000
• Pacientes com dor crônica: 50.000.000

Instituições de Pesquisa Médica

A empresa se envolve com 875 instituições de pesquisa médica com foco na pesquisa de doenças inflamatórias.

Tipo de instituição	Número de instituições
Centros de pesquisa afiliados à universidade	612
Institutos de pesquisa independentes	263

Ampio Pharmaceuticals, Inc. (AMPE) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Ampio Pharmaceuticals relatou despesas de P&D totalizando US $ 4,2 milhões. O foco da pesquisa da empresa envolve principalmente desenvolvimentos terapêuticos em medicina regenerativa e doenças inflamatórias.

Ano fiscal	Despesas de P&D	Porcentagem do orçamento operacional total
2023	$4,200,000	62%
2022	$3,850,000	58%

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos para a Ampio Pharmaceuticals em 2023 foram de aproximadamente US $ 3,6 milhões, cobrindo vários estudos de fase para seus candidatos terapêuticos.

• Ensaios de Fase I: US $ 1.200.000
• Ensaios de Fase II: US $ 2.100.000
• Preparativos de estudo regulatório: US $ 300.000

Investimentos de conformidade regulatória

Os custos de conformidade regulatórios para 2023 totalizaram US $ 850.000, incluindo taxas de envio da FDA, preparação de documentação e serviços de consultoria externa.

Aquisição de funcionários e talentos científicos

Categoria de pessoal	Custo anual	Número de funcionários
Cientistas de pesquisa	$2,500,000	35
Pesquisadores clínicos	$1,800,000	25
Equipe administrativo	$1,200,000	20

Proteção e manutenção da propriedade intelectual

Os custos de propriedade intelectual para 2023 foram de US $ 450.000, cobrindo o registro de patentes, manutenção e proteção legal das tecnologias proprietárias.

• Taxas de arquivamento de patentes: US $ 250.000
• Consulta legal: US $ 150.000
• Manutenção de patentes: US $ 50.000

Ampio Pharmaceuticals, Inc. (AMPE) - Modelo de negócios: fluxos de receita

Potenciais acordos futuros de licenciamento de medicamentos

A partir do quarto trimestre 2023, a Ampio Pharmaceuticals não relatou nenhum acordo de licenciamento de medicamentos ativo. A receita total potencial de licenciamento permanece não revelada.

Bolsas de pesquisa e financiamento

Ano	Fonte de concessão	Quantia
2023	NIH Small Business Innovation Research	$298,750
2022	Departamento de Defesa	$175,000

Desenvolvimento de produtos farmacêuticos

O Pipeline de desenvolvimento atual se concentra nas tecnologias terapêuticas proprietárias, sem receita comercial confirmada a partir de 2024.

Parcerias de pesquisa colaborativa

• Campus Médico da Universidade do Colorado Anschutz
• Programa Nacional de Pesquisa para Pesquisa de Institutos Nacionais de Saúde

Vendas potenciais de produtos terapêuticos

Nenhuma venda de produtos terapêuticos atuais informados. A receita principal da empresa permanece do financiamento da pesquisa e da potencial comercialização futura de produtos.

Métrica financeira	2023 valor
Receita total	$412,650
Despesas de pesquisa	$3,750,000

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Value Propositions

You're looking at the Value Propositions for Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025, which, frankly, centers less on product delivery and more on financial and legal closure, given the company's strategic shift.

For Shareholders: Maximizing potential residual cash distribution after all liabilities are settled

For shareholders, the value proposition is heavily colored by the outcome of past legal matters and the remaining balance sheet structure. Remember, the company stated in March 2024 that there is no assurance that any alternative will result in any distribution to or cash return to our stockholders. Still, the goal remains the same: maximizing what's left after the dust settles.

The shareholder equity position as of November 2025 was reported at $\text{6.44}$ million USD. This figure sits against the total liabilities, which were $\text{7.56}$ million USD in the same period. This suggests a deficit between total liabilities and total equity on paper, which complicates any residual distribution scenario.

A concrete, past financial event impacting this group was the $\text{\$3M}$ Shareholder Settlement, where the claim deadline was set for January 13, 2025. For those who filed, the estimated average recovery, assuming a $\text{25\%}$ participation rate, was around $\text{\$0.08}$ per share. The company previously noted in its 2022 filings that if it ceased operations and liquidated assets, it was unlikely cash would be available for distributions to stockholders.

Here's a quick look at the key balance sheet components as of the latest available data:

Metric	Amount (USD Millions)	As of Date
Total Liabilities	$\text{7.56}$	November 2025
Total Current Liabilities	$\text{4.28}$	November 2025
Total Equity	$\text{6.44}$	November 2025

For Creditors: Orderly and legal resolution of all outstanding financial obligations

For creditors, the value proposition is tied directly to the company's ability to service its obligations, particularly the current ones, through its available assets. The focus here is on the Total Liabilities figure of $\text{7.56}$ million USD as of November 2025.

The immediate concern for creditors involves the current obligations, which stood at $\text{4.28}$ million USD in current liabilities in November 2025. This is the amount that needs to be addressed first in any wind-down or restructuring scenario.

The company has taken steps to conserve cash, including expected annual savings of approximately $\text{\$4.6}$ million from streamlining operations. This cash conservation effort directly supports the ability to meet financial obligations, which is the primary value for creditors.

The resolution process is framed by these key financial realities:

• Total Liabilities stood at $\text{7.56}$ million USD as of November 2025.
• Total Current Liabilities were $\text{4.28}$ million USD in November 2025.
• The company is focused on cash conservation measures.

For Regulators: Compliance with all final legal and dissolution reporting requirements

The value proposition for regulators, like the Securities and Exchange Commission (SEC), is the commitment to a clean, legal exit from active public reporting. Ampio Pharmaceuticals, Inc. announced in March 2024 its determination to voluntarily delist its common stock from the NYSE American and pursue SEC deregistration.

This action directly addresses the regulatory burden. The plan involved filing a Form 15 with the SEC around April 15, 2024, to suspend reporting obligations under the Exchange Act, which includes Forms 10-K, 10-Q, and 8-K.

The key compliance points are:

• Intent to file Form 15 to suspend reporting obligations.
• The process aims to terminate other SEC filing requirements upon the effectiveness of deregistration.
• The company is navigating the resolution of pending legal proceedings.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Customer Relationships

You're looking at the customer relationships for Ampio Pharmaceuticals, Inc. as of late 2025, and honestly, it's less about selling a product and more about managing the final administrative wind-down following the dissolution approved in August 2024. The relationship with the former customer base-the stockholders-is now almost entirely transactional and governed by legal necessity.

Transactional communication with shareholders via the transfer agent

The primary point of contact for former stockholders regarding their equity is through the designated transfer agent, Equiniti. This communication is strictly transactional, dealing with the mechanics of any final cash distribution, which is contingent on settling all legal obligations and receiving approval from the Delaware Chancery Court. As of November 28, 2025, the remaining market capitalization stood at a nominal $5.9K, which gives you a sense of the scale of assets being managed through this final process. You should direct any specific questions about stockholdings to your broker or Equiniti, as the company itself is dissolved.

• Address stockholding questions to Equiniti.
• Cash distribution timing is subject to court approval.
• The company discontinued development of Ampion in February 2024.

Formal legal and administrative correspondence with legal counsel and courts

This is where the bulk of the remaining activity lies. The company's focus is on finalizing the settlement of past litigation. You'll recall the securities fraud class action and the consolidated derivative actions. A settlement in principle was reported in January 2024, and the Court preliminarily approved the securities settlement on September 24, 2024. This proposed settlement created a $3,000,000 Settlement Fund, plus interest, less fees and expenses. The deadline for stockholders to object or exclude themselves from this settlement was January 29, 2025. All ongoing administrative correspondence is channeled through legal counsel to the Delaware Chancery Court to secure the final order necessary to distribute any remaining cash after these obligations are met. The company voluntarily delisted and began SEC deregistration in April 2024, meaning formal SEC reporting relationships have been terminated.

Here's a quick look at the key administrative touchpoints governing the final phase:

Administrative Entity	Key Action/Status	Relevant Date/Amount
Delaware Chancery Court	Approves final cash distribution plan	Post-settlement finalization
Securities Class Action Settlement Fund	Proposed principal amount	$3,000,000
Securities Settlement Opt-Out/Object Deadline	Final administrative cutoff for class members	January 29, 2025
Transfer Agent	Handles shareholder account inquiries	Equiniti

Minimal, necessary contact with vendors for contract termination

With the dissolution effective August 16, 2024, and the discontinuation of the OA-201 program in February 2024, the need for ongoing vendor relationships has dropped to near zero. Any remaining contact is purely administrative, focused on finalizing any outstanding termination clauses or settling final invoices related to the wind-down of operations and the cessation of clinical development activities. The relationship is defined by closure, not ongoing service provision. The company's operational footprint is minimal, reflecting the focus on asset liquidation and legal finalization rather than business continuity.

• OA-201 program terminated in February 2024.
• Vendor contact limited to contract finalization.
• Reporting obligations under the Exchange Act terminated in April 2024.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Channels

You're looking at the channels Ampio Pharmaceuticals, Inc. uses to communicate with stakeholders and facilitate post-operational activities as of late 2025, given the company's wind-down status following the termination of its primary development program.

Corporate website for dissolution updates and official notices

The corporate website remains a primary, albeit static, channel for official notices related to the company's ongoing wind-down and the suspension of its SEC reporting obligations. Key contact points listed for inquiries include:

• Chief Executive Officer email: mmartino@ampiopharma.com
• General and Proxy inquiries email: info@ampiopharma.com

The company completed its voluntary delisting from the NYSE American on or about April 14, 2024, and intended to suspend its reporting obligations by filing Form 15 around April 15, 2024.

Legal administrators for processing shareholder settlement claims

The processing of past shareholder claims is managed through a court-appointed administrator, a critical channel for former investors seeking recovery from the settled litigation. The proposed settlement amount is $3,000,000.

Here are the key details regarding the settlement administration:

Settlement Administrator	Simpluris, Inc.
Total Settlement Fund	$3,000,000
Claim Submission Deadline	January 13, 2025
Final Approval Hearing Date	February 19, 2025
Claimant Purchase Period	December 29, 2020, through August 2, 2022
Estimated Average Recovery Per Share	Approximately $0.015 (post-deductions)

The distribution of the Net Settlement Fund to eligible Settlement Class Members is contingent upon the Court's final approval, which was sought in February 2025.

OTC Pink Market for common stock trading (following voluntary delisting in 2024)

Following the voluntary delisting from the NYSE American in 2024, Ampio Pharmaceuticals, Inc. common stock trades on the OTC Markets, specifically the OTC Pink Market, under the ticker AMPE. This is the current venue for any remaining public trading activity. The operational scale is minimal, reflecting the company's wind-down status.

Current trading metrics as of December 3, 2025, illustrate this:

Metric	Value as of Dec 3, 2025
Stock Price	0.0052 USD
Market Capitalization	$5.9 thousand
52-Week Range	0.0001 USD to 0.1643 USD
Earnings Per Share (TTM)	-10.66
Total Employees	6

The stock has shown extreme price compression, with the market cap at $5.9K as of November 28, 2025, compared to a historical high market cap of 34.12M since March 10, 2010. Trading volume is also thin, with an average daily volume of 1.32K shares.

Finance: review the cash position against the remaining administrative costs by next Tuesday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Customer Segments

You're looking at the final stages of a company's financial obligations, not a growth market. For Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025, the customer segments are essentially the parties due a final distribution or settlement payment stemming from past corporate or legal actions, not product sales.

The primary focus is on resolving the securities litigation, which dictates the largest defined financial outflow. This means the 'customers' are claimants against the corporate estate or the legal entities managing that distribution.

Former shareholders of AMPE common stock seeking final distribution

This group consists of investors who acquired Ampio common stock during the defined class period and submitted a valid claim form by the deadline of January 13, 2025.

• Purchased or acquired AMPE common stock between December 29, 2020, and August 2, 2022.
• Eligible to share in the distribution of the Net Settlement Fund.
• The estimated average recovery per share, after deductions for fees and expenses, was approximately $0.015 per share.
• If 100% of eligible investors filed claims, the estimated average recovery was $0.02 per share before deductions.

Legal administrators and claimants involved in the $3 million settlement

This segment includes the court-appointed administrators and the legal counsel managing the distribution of the $3,000,000 Settlement Fund. Their role is to process claims and deduct their approved fees and expenses from the gross fund before the remainder goes to the shareholders.

Here's a quick math breakdown of the initial $3,000,000 fund allocation, which directly impacts the Net Settlement Fund available for claimants:

Component	Amount/Percentage	Reference Point
Total Settlement Fund	$3,000,000	Cash established for the settlement.
Attorneys' Fees	28% of the Settlement Fund	To be paid to Lead Counsel.
Lead Counsel Expenses	Up to $75,000	Plus accrued interest.
Lead Plaintiffs' Costs	Up to $5,000	For reasonable costs and expenses.

Remaining creditors and vendors with outstanding invoices

This segment represents entities that provided goods or services to Ampio Pharmaceuticals, Inc. and hold outstanding invoices. While the securities settlement is a defined financial event, the status and total amount owed to general creditors are not publicly detailed in the same manner as the class action settlement. Still, these parties are crucial stakeholders in any final corporate wind-down or asset distribution process post-litigation resolution.

• These parties are generally addressed through bankruptcy proceedings or direct liquidation agreements, which are separate from the securities class action.
• The company's financial reporting, such as the Amended Annual Report (10-k/a) filed as of November 25, 2025, would contain the latest figures on total liabilities, though specific vendor balances aren't itemized here.
• The priority of payment for these creditors relative to the settlement fund is a key financial consideration in the overall wind-down strategy.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Cost Structure

The Cost Structure for Ampio Pharmaceuticals, Inc. as of late 2025 reflects a significant shift towards wind-down activities following the voluntary delisting and intent to terminate SEC reporting obligations announced in early 2024.

The primary cost drivers are concentrated in final legal obligations, minimal essential overhead, and the execution of the deregistration process. Here is a breakdown of the relevant financial figures:

Cost Category	Financial Amount (USD)	Reference Period/Context
Legal and professional fees for dissolution and litigation defense	\$6,896,000	Professional Fees (2022 Annual)
Minimal remaining personnel costs for essential corporate functions	\$1,485,000	Salaries and benefits (2022 Annual)
Facility and office sublease costs, targeting annual savings	\$4,600,000	Targeted Annual Savings
Administrative costs for SEC deregistration and final reporting	No specific 2025 figure available	Post-Form 15 Filing Phase
Securities Settlement Fund (One-time Cost)	\$3,000,000	Settlement Fund (2024 Preliminary Approval)

You should note the following specific cost elements that feed into the overall structure:

• Legal and professional fees for dissolution and litigation defense, which historically included significant amounts for investigations and lawsuits, such as the \$4.4 million increase in professional fees noted in 2022 related to legal costs.
• Minimal remaining personnel costs for essential corporate functions, which were \$1,141,000 for salaries and benefits in 2021, increasing to \$1,485,000 in 2022 before expected reductions for wind-down.
• Facility and office sublease costs, targeting annual savings of \$4.6 million, which aligns with the prior facility lease expiring in September 2024.
• Administrative costs for SEC deregistration and final reporting, which follow the filing of Form 15 to suspend obligations like Forms 10-K, 10-Q, and 8-K.

The litigation component includes the one-time cost associated with the securities settlement:

• The proposed Settlement Fund was set at \$3,000,000 plus interest.
• Attorneys for Lead Plaintiffs sought 28% of the Settlement Fund plus up to \$75,000 for expenses.
• Lead Plaintiffs sought an award of up to \$5,000 for reasonable costs and expenses.

General and Administrative expenses in the last reported full year totaled \$11,466,000, a significant increase from the \$8,671,000 reported the prior year.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025. Given the company's status as a pre-revenue stage biopharmaceutical entity, the revenue profile is heavily weighted toward non-operating sources, which is typical for a firm focused on preclinical development like their AR-300 program. Honestly, the core business activity isn't selling drugs yet; it's about managing capital until a major clinical or strategic event occurs.

The structure of revenue streams reflects a company in a holding or transition phase, relying on its existing financial assets rather than product sales. To be fair, this is a common, albeit precarious, position for many development-stage biotechs.

Interest income generated from remaining cash reserves is a key component. Based on the latest available income statement data for the nine months ended September 30, 2023, the company recognized $0.1 million in interest income, which was partially offset by a derivative gain of $1.2 million for that period. This income is directly tied to the size and management of their liquid assets.

Potential proceeds from the sale or licensing of residual intellectual property (IP) remain a theoretical, high-impact stream. While Ampio Pharmaceuticals, Inc. has historically held a portfolio of patents, including those related to their discontinued Ampion product and the ongoing AR-300 development, there are no publicly reported figures for 2025 regarding any specific licensing agreements or asset sales. The IP strategy remains a potential lever for future capital events, but it hasn't translated into realized revenue for the current period.

The required figure for operating revenue from drug sales or development activities in 2025 is $0. This aligns with the company's historical reporting as a pre-revenue stage entity focused on preclinical work, as confirmed by their 2022 filings.

Here's a quick look at the latest concrete financial figures we have to anchor these revenue expectations:

Financial Metric	Latest Reported Value (USD)	Reporting Date/Period End
Operating Revenue (Required for 2025)	$0	Fiscal Year 2025
Interest Income (Latest Reported)	$0.1 million	Nine Months Ended September 30, 2023
Cash and Equivalents (Latest Reported Balance)	$5.375 million	September 30, 2023
Cash and Cash Equivalents (Prior Year End)	$12.7 million	December 31, 2022

The reliance on interest income is a function of the cash balance. You'll want to track the cash flow statement closely, as the burn rate dictates how long this interest income stream can persist without new financing or a strategic transaction. The cash balance as of September 30, 2023, was $5.375 million, adjusted for a 20-to-1 reverse stock split effected in September 2023.

The potential for IP monetization is a binary event-it's either zero or a significant, non-recurring cash infusion. The company's focus on AR-300 preclinical data is the primary driver for any future value realization, which could lead to licensing deals, but that isn't a predictable revenue stream right now.

For your planning, keep an eye on these key areas that feed into the revenue picture:

• Cash burn rate from operating expenses.
• Progress and data readouts for the AR-300 program.
• Any public statements regarding strategic alternatives, including potential M&A or asset divestitures.

Finance: draft 13-week cash view by Friday.